The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience

BACKGROUND. Pemetrexed is a commonly used treatment for platinum-resistant advanced urothelial carcinoma (UC) based on objective response rates of 8% and 28% in two small phase II studies. To address the discrepancy in reported response rates and to assess efficacy and toxicity outside of a clinical...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Bambury, Richard M., Benjamin, David J., Chaim, Joshua L., Zabor, Emily C., Sullivan, John, Garcia-Grossman, Ilana R., Regazzi, Ashley M., Ostrovnaya, Irina, Apollo, Aryln, Xiao, Han, Voss, Martin H., Iyer, Gopa, Bajorin, Dean F., Rosenberg, Jonathan E.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2015
Témata:
Genitourinary Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425381/
https://ncbi.nlm.nih.gov/pubmed/25845990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0354
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky